US8815594B2

US8815594B2 - Hybrid tissue scaffold for tissue engineering

Info

Publication number: US8815594B2
Application number: US13/712,583
Authority: US
Inventors: Jeffrey Nelson HARRIS; Jian Ling; Xingguo Cheng
Original assignee: Southwest Research Institute SwRI
Current assignee: Southwest Research Institute SwRI
Priority date: 2012-12-12
Filing date: 2012-12-12
Publication date: 2014-08-26
Anticipated expiration: 2032-12-12
Also published as: US20140161841A1; US20150050736A1; US9752117B2

Abstract

A hybrid tissue scaffold is provided which comprises a porous primary scaffold having a plurality of pores and a porous secondary scaffold having a plurality of pores, wherein the secondary scaffold resides in the pores of the primary scaffold to provide a hybrid scaffold. The pores of the porous primary scaffold may have a pore size in a range of 0.50 mm to 5.0 mm, and the pores of the porous secondary scaffold may have a pore size in a range of 50 μm to 600 μm. The primary scaffold may provide 5% to 30% of a volume of the hybrid scaffold.

Description

FIELD OF THE INVENTION

The present disclosure relates to a hybrid tissue scaffold for tissue implants and methods of for use thereof. The hybrid tissue scaffold includes a primary three-dimensional (base) scaffold which supports or otherwise carries a secondary three-dimensional scaffold, particularly within the pores thereof.

BACKGROUND

Engineered tissue implants require a tissue scaffold that is preferably made of similar materials to the tissue that will be replaced by the engineered tissue implant. This requires using biomaterials such as, but not limited to, collagen, fibrin, and glycosaminoglycans (GAGs). However, while these materials may provide the correct biomaterial environment, they lack the mechanical strength required to be implanted. Such forces may be generated from in situ forces, such as pressure from fluids passing through or by the implant. Further, the tissue implants need to be able to withstand the forces of being handled and surgically implanted by the surgeon. This is a common, long standing problem that has made designing a tissue engineering implant very difficult.

Many different techniques have been used to try to overcome the lack of mechanical strength in scaffolds, and the corresponding lack of strength in the implant. These include processing techniques such as crosslinking the materials. However, this typically does not create sufficient increased strength. In addition, the crosslinkers are usually cytotoxic, which adds the complexity of thoroughly rinsing the samples to remove excess crosslinker. Other techniques have copolymerized the biomaterials with a stiffer, usually synthesized, polymer. This greatly increases the cost of manufacturing the material and can be hard to fabricate the material into a scaffold. In addition, scaffolds have been developed from a relatively stiff synthesized polymer with pore sizes in the range of a few hundreds of microns in diameter, which have then been coated with a biomaterial. This technique can provide the strength required, but results in a mostly synthetic scaffold with minimal biomaterial that the cells cannot remodel. Once the biomaterials are degraded only the synthetic polymer remains.

SUMMARY

The present disclosure provides new structures and methods to improve the mechanical strength of a hybrid tissue scaffold of an engineered tissue implant. The disclosure provides a hybrid tissue scaffold comprising a primary three-dimensional (base) scaffold which supports or otherwise carries a secondary three-dimensional scaffold, particularly within the pores thereof. More particularly, the porous primary scaffold may have a pore size in a range of between and including 0.50 mm to 5.0 mm, while the secondary scaffold may have a relatively smaller pore size, such as in the range between and including 50 μm to 600 μm (microns).

The primary scaffold may be fabricated from a variety of polymer materials and have different pore geometries to achieve the desired strength for a given application. The primary scaffold provides a framework or skeleton into which the secondary scaffold can be introduced. In contrast to the primary scaffold, the secondary scaffold may particularly be formed of a natural biomaterial, such as a naturally occurring polymer. The naturally occurring polymer may be a protein (e.g. collagen, fibrin) or a carbohydrate (e.g. a polysaccharide such as chitosan, glycosaminoglycan).

The biomaterial, which may be in the form of a hydrogel, may be injected into the pores of the primary scaffold and reside therein. The biomaterial may be injected with or without seeding cells, and may be processed to provide a micro porous scaffold with designed pore size and geometries.

In the foregoing manner, the primary scaffold will only occupy a relatively smaller volume of the hybrid scaffold or engineered tissue implant, yet provide the needed strength of the implant for implantation while the biomaterial provides the appropriate environment for the seeding stem cells to proliferate.

The hybrid tissue scaffold or engineered tissue implant may accelerate the wound healing process since they are able to: 1) cover the wound site to keep the wound moist and to reduce the risk of infection; 2) reduce tissue regeneration time through the incorporation of functional tissue developed in vitro; and 3) provide a source of stem cells to the wound sites for tissue regeneration.

In certain embodiments, a hybrid tissue scaffold may comprise a porous primary scaffold having a plurality of pores, and a porous secondary scaffold having a plurality of pores, wherein the secondary scaffold resides in the pores of the primary scaffold to provide a hybrid scaffold. The pores of the porous primary scaffold may have a pore size in a range of 0.50 mm to 5.0 mm, and the pores of the porous secondary scaffold have a pore size in a range of 50 μm to 600 μm. The primary scaffold may provide 5% to 30% of a volume of the hybrid scaffold. In other embodiments, the pores of the porous primary scaffold may have a pore size in a range of 1 mm to 4 mm, and the pores of the porous secondary scaffold may have a pore size in a range of 100 μm to 500 μm.

In certain embodiments, the porous primary scaffold may be formed of a synthetic polymer, and the synthetic polymer may be biodegradable in a human body. The synthetic polymer may be polyester, and may particularly include polycaprolactone (PCL).

In certain embodiments, the secondary scaffold may be formed of a biomaterial which provides an environment to culture living cells therein and promote attachment, migration, proliferation, and/or vascularization of the cells. The biomaterial may be formed of a naturally occurring polymer. The naturally occurring polymer may be a protein (e.g. collagen, fibrin) and/or a carbohydrate. The secondary porous scaffold may be in the form of a hydrogel or porous scaffold.

In certain embodiments, a plurality of living cells may be seeded to at least one of the primary scaffold and the secondary scaffold. The cells may comprise at least one of endothelial, fibroblast and/or stem cells.

In certain embodiments, a method to provide a tissue scaffold comprises forming a hybrid scaffold comprising a porous primary scaffold having a plurality of pores and a porous secondary scaffold having a plurality of pores, wherein the secondary scaffold resides in the pores of the primary scaffold to provide the hybrid scaffold. The pores of the porous primary scaffold may have a pore size in a range of 0.50 mm to 5.0 mm, and the pores of the porous secondary scaffold may have a pore size in a range of 50 μm to 600 μm. The primary scaffold may provide 5% to 30% of a volume of the hybrid scaffold.

In certain embodiments, the method may further comprise forming the porous primary scaffold with the plurality of pores and introducing the porous secondary scaffold into the pores of the porous primary scaffold.

In certain embodiment, the method may further comprise injecting the porous secondary scaffold into the pores of the porous primary scaffold.

In certain embodiments, the porous secondary scaffold is in the form of a hydrogel, and the method may further comprise injecting the hydrogel into the pores of the porous primary scaffold.

In certain embodiments, forming the hybrid scaffold may be performed in situ during a surgical procedure on a human body.

In certain embodiments, the method may further comprise fitting the porous primary scaffold to a tissue treatment site of a human body before introducing the porous secondary scaffold into the pores of the porous primary scaffold.

FIGURES

The above-mentioned and other features of this disclosure, and the manner of attaining them, will become more apparent and better understood by reference to the following description of embodiments described herein taken in conjunction with the accompanying drawings, wherein:

FIG. 1 is an image of a primary scaffold according to one embodiment of the present disclosure;

FIG. 2 is an image of a hybrid scaffold according to one embodiment of the present disclosure which makes use of the primary scaffold of FIG. 1;

FIG. 3 is an image of the microstructure of PCL-collagen hybrid scaffold of FIG. 2 imaged by an environmental electron scanning microscope (ESEM);

FIG. 4 is an image of live/dead staining of cells within the collagen of a PCL-collagen hybrid scaffold; and

FIG. 5 is an image of live/dead staining of cells on the surface of the polycaprolactone of a PCL-collagen hybrid scaffold.

DETAILED DESCRIPTION

It may be appreciated that the present disclosure is not limited in its application to the details of construction and the arrangement of components set forth in the following description or illustrated in the drawings. The invention(s) herein may be capable of other embodiments and of being practiced or being carried out in various ways. Also, it may be appreciated that the phraseology and terminology used herein is for the purpose of description and should not be regarded as limiting as such may be understood by one of skill in the art.

Referring now to figures, an exemplary primary scaffold according to the present invention is shown in FIG. 1 at reference character 10. The primary scaffold 10 provides a framework or skeleton into which a secondary scaffold may be introduced (e.g. injected or otherwise filled) into the plurality of pores 12 thereof. The pores of the primary scaffold 10 may have a pore size in a range of between and including 0.50 mm to 5.0 mm. More particularly, the pores of the primary scaffold 10 may preferably have a pore size in a range of between and including 1.0 mm to 4.0 mm. The primary scaffold 10 itself may have a porosity level in a range of between and including 50% to 99%.

The primary scaffold 10 of FIG. 1 may preferably be made of a biodegradable polymer such as a polyester polymer including polycaprolactone (PCL) or poly(lactic-co-glycolic acid (PLGA). PCL reportedly has melting point of about 60° C. and a glass transition temperature of about −60° C. Reference to biodegradable may be understood herein as the ability to undergo enzymatic degradation or nonenzymatic hydroylysis and to provide non-toxic metabolites that may then be eliminated by the body. It is therefore contemplated herein that biodegradable polymers suitable for preparation of the primary scaffold 10 may also include polyurethane, poly (urethane urea), polyhydroxyalkanoates (PHAs), poly(1-lactic acid) (PLLA), polyanhydrides, polyfumerates, poly(n-isopropylacrylamide, or polypeptides.

The fabrication of the primary scaffold herein may proceed by at least two related methods. The first method may be generally understood as providing a solution of the biodegradable polymer (polyester) that is mixed with insoluble inorganic salt particulate wherein the salt has a size range of 0.50 to 5.0 mm. This is then followed by relatively rapid cooling where the rate of cooling is such that the polyester (PCL) will precipitate followed by evaporating the solvent before treatment with water to dissolve the salt and provide a pore size range of 0.50 mm-5.0 mm. Preferably, the rate of cooling is 1 degree Celsius per minute. Exemplary salts include NaCl, NaHCO₃, urea, and various sugars.

A preferred fabrication according to the first method noted above is to start with a 10% (w/w) PCL solution made by dissolving PCL in organic solvents, such as 65% (w/w) chloroform and methanol solution. The PCL solution was then mixed with a salt that was previously sieved to the range of 0.85 mm to 1.40 mm. The solution was then placed in a freezer at −20° C. to provide PCL precipitation. The samples were then placed in a fume hood to allow the solvents to evaporate. Next, the samples are placed in second solvent such as water to dissolve out the salt resulting in the formation of a porous PCL scaffold 10. As noted, such porous PCL scaffold has a pore size range of 0.50-5.0 mm. See again, FIG. 1.

A second related method to fabricate the primary scaffold 10 may proceed by mixing a salt in a size range of 0.50 mm-5.0 mm with biodegradable polymer particulate having a size less than or equal to 0.5 mm, or in the range of 0.5 mm to 5.0 mm. The biodegradable polymer (e.g. PCL) may then be heated at a temperature sufficient to sinter the PCL particles or treated with solvent to form a continuous phase of the PCL around the salt. Sintering may be understood as heating to a sufficient temperature to join the PCL particles and the treatment with solvent is also such that the particles are joined to form the identified continuous phase. The salt is such that it again will not dissolve or melt, as the salt may then again define the porosity to be achieved when the salt is ultimately removed from the continuous phase of biodegradable polymer (PCL). That is, the salt, present at a size of 0.50 mm to 5.0 mm, is dissolved to obtain the porous PCL scaffold 10. The pore size of the PCL scaffold may again be in the range of 0.50 mm to 5.0 mm, and preferably in the range of 1.0 mm to 4.0 mm (due to use of correspondingly lower salt size). The PCL scaffold 10 then once again serves as the skeleton of the hybrid tissue scaffold/engineered tissue implant disclosed herein, and provides a framework for the hybrid tissue scaffold/implant to withstand the forces during in vivo implantations. As noted above, the PCL scaffold is configured such that it will amount to 5.0% to 30.0% of the hybrid scaffold volume, more preferably in the range of 10.0% to 20.0% by volume, and more preferably, 14.0% to 16.0% by volume.

Once the primary scaffold 10 is fabricated, a porous secondary scaffold 20 may be introduced into the pores 12 of the primary scaffold 10. Referring now to FIG. 2, a secondary scaffold 20 is shown residing in, such as by being injected into the pores in the primary scaffold 10. The secondary scaffold 20 is preferably formed of a biomaterial (any matter, surface, or construct that interacts with biological systems of a human body) and which provides an environment to culture living seeded cells and promote cell attachment, migration, proliferation, and/or vascularization. To facilitate injection and biological interaction, the secondary scaffold 20 may particularly be in the form of a hydrogel. A hydrogel herein may be understood as a network of polymer chains that are hydrophilic in which water is the dispersion medium.

The pores of the secondary scaffold 20 may have a pore size in a range of between and including 50 μm to 600 μm. More particularly, the pores of the secondary scaffold 20 may have a pore size in the range of 200 μm to 500 μm. The secondary scaffold 20 may have a porosity level in a range of between and including 50% to 99% by volume.

The biomaterial may be formed of a naturally occurring polymer which is a protein (e.g. collagen, fibrin) and/or a carbohydrate e.g. a polysaccharide such as chitosan, glycosaminoglycan. FIG. 2 shows a secondary scaffold 20 of collagen introduced to and residing in the pores 12 of primary scaffold 10, the combination of which provides a PCL-collagen hybrid scaffold 30.

FIG. 3 shows the microstructure of PCL-collagen hybrid scaffold 30 imaged by an environmental electron scanning microscope (ESEM). Arrow A illustrates the location of the PCL primary scaffold 10, while arrow B illustrates the location of the collagen secondary scaffold 30. The collagen scaffold 30 has interconnected pores with an average diameter of 250 μm within the collagen material and the porosity was about 70%.

As noted, the primary scaffold herein may provide 5.0% to 30.0% of the hybrid scaffold volume. In this manner, the primary scaffold 10 may provide the needed strength of the hybrid scaffold/implant for implantation while the filler biomaterial of the secondary scaffold 20 provides the needed environment for seeded stem cells to proliferate. While the primary PCL scaffold 10 therefore represents only a portion of the volume of the PCL-collagen hybrid scaffold 30, the PCL scaffold 10 may now unexpectedly enhance the mechanical stiffness of the PCL-collagen hybrid scaffold 30 while preserving the ability of the scaffold to provide the correct material environment for cell proliferation.

More specifically, it has been found that the PCL-collagen hybrid scaffold 30 exhibits a Young's modulus in the range of 0.1 MPA to 100 GPa, more preferably, 1.80 to 2.2 MPa. Young's modulus of the hybrid scaffold is measured by unconfined compression. By comparison, it has been found that scaffolds which rely upon only crosslinked collagen (where crosslinking was employed to increase the modulus value and overcome the problem of relatively poor mechanical strength), indicate Young's modulus value of about 23 kPa. As can therefore be appreciated, the present hybrid scaffold provides magnitudes of order improvement in mechanical property characteristics, such as Young's modulus, thereby achieving the goal of strength improvement in the hybrid scaffold without the need to crosslink and/or extraction of chemical crosslinking agents. In addition, the present hybrid skeleton approach allows for mechanical property improvement without the need to crosslink the biomaterial. A scaffold is nonetheless produced that withstands loading forces during implantation where it may be press-fit into a selected location.

Additional embodiments of the hybrid scaffold 30 include using fibrin as the secondary scaffold 20 to be introduced into the pores of the primary scaffold 10 instead of collagen. Both the PCL-collagen hybrid scaffold 30 and the PCL-fibrin hybrid scaffold 30 have been found to successfully house seeded cells, such as stem, endothelial, and fibroblast cells, and allow them to create extracellular matrix and remodel the material in an in vitro culture. FIG. 4 shows live/dead staining of cells within the collagen of the PCL-collagen hybrid scaffold 30. FIG. 5 shows live/dead staining of cells on the surface of the polycaprolactone of the PCL-collagen hybrid scaffold 30.

Thus, the foregoing technique may also provide enhanced versatility of applications. The pores of the primary scaffold may be injected or otherwise filled with the biomaterial and processed to form the hybrid tissue scaffold/engineered implant prior to use thereof. The hybrid tissue scaffold therefore relies only upon the presence of the primary scaffold of the indicated polymers and secondary scaffold material as disclosed herein and avoids dependence on the use of any other components (e.g. crosslinking agents in the secondary scaffold or the use of copolymer structure in the secondary scaffold biomaterial). The hybrid tissue scaffold also does not rely upon the presence of glass. Accordingly, the present disclosure provides transplantable hybrid tissue scaffolds/implants that can be vascularized or even pre-developed into functional tissue in vitro and then transplanted in vivo as engineered tissue substitute at a tissue treatment site. The hybrid tissue scaffold/engineered implant may be configured to connect with host blood vessels in vivo to supply oxygen and nutrition to cells thereof immediately after the implantation.

In addition, as alluded to above, the bare primary scaffold can be shapeable as to conform to the anatomical shape of a wound or other tissue treatment site (e.g. press fit and/or cut to fit) and then the biomaterial can be injected into the primary scaffold in situ in a minimally invasive procedure. The biomaterial is configured to integrate into surrounding host tissue to achieve wound healing. The hybrid tissue scaffold or engineered tissue implant may comprise a same or similar tissue type as the lost tissue at the tissue treatment site. The tissue scaffold construct/engineered tissue implant may be developed into functional tissue types such as muscle, bone, cartilage, and epithelial in vitro. Further, the hybrid tissue scaffold may be loaded with drugs or growth factors to better control the integration into the surrounding tissue.

While a preferred embodiment of the present invention(s) has been described, it should be understood that various changes, adaptations and modifications can be made therein without departing from the spirit of the invention(s) and the scope of the appended claims. The scope of the invention(s) should, therefore, be determined not with reference to the above description, but instead should be determined with reference to the appended claims along with their full scope of equivalents. Furthermore, it should be understood that the appended claims do not necessarily comprise the broadest scope of the invention(s) which the applicant is entitled to claim, or the only manner(s) in which the invention(s) may be claimed, or that all recited features are necessary.

Claims

What is claimed is:

1. A method of forming a hybrid tissue scaffold comprising:

forming a solution of biodegradable polymer in the presence of an inorganic salt wherein the inorganic salt is water soluble and has a particulate size in a range of 0.50 to 5.0 mm;

cooling said solution to precipitate said biodegradable polymer followed by treatment with water to dissolve said inorganic salt wherein the biodegradable polymer is recovered as a porous primary scaffold having a pore size in a range of 1 mm to 4 mm;

introducing into said primary scaffold a biomaterial comprising a hydrogel including living cells and forming a secondary scaffold from said biomaterial including living cells, wherein the secondary scaffold resides in the pores of the primary scaffold to provide a hybrid scaffold;

wherein said biomaterial provides an environment to culture the living cells and said biomaterial has a pore size of 50 μm to 600 μm; and

wherein said primary scaffold is present at 5.0% to 30.0% by volume of said hybrid scaffold and said hybrid scaffold has a Young's modulus of 0.1 MPA to 100 GPa.

2. The method of claim 1 wherein said biodegradable polymer comprises a polyester polymer.

3. The method of claim 1 wherein said biomaterial does not contain any crosslinking.

4. The method of claim 1 wherein said biodegradable polymer is recovered as a porous primary scaffold having a pore size in the range of 1.0 mm to 4.0 mm.

5. The method of claim 1 wherein the primary scaffold is present at 10.0% to 20.0% by volume.

6. The method of claim 1 wherein said biomaterial has a porosity of 50% to 99% by volume.

7. The method of claim 1 wherein said biomaterial further comprises at least one of a protein and a carbohydrate.

8. A method of forming a hybrid tissue scaffold comprising:

mixing biodegradable polymer particulate size in a range of 0.50 mm to 5.0 mm with an inorganic salt having a particulate size in a range of 0.5 mm to 5.0 mm;

sintering or treating said biodegradable polymer with solvent to form a continuous phase of the biodegradable polymer around said salt;

dissolving said inorganic salt wherein said biodegradable polymer is recovered as a porous primary scaffold having a pore size in a range of 1 mm to 4 mm;

9. The method of claim 8 wherein said biodegradable polymer comprises a polyester.

10. The method of claim 8 wherein said biomaterial does not contain any crosslinking.

11. The method of claim 8 wherein said biodegradable polymer is recovered as a porous primary scaffold having a pore size in the range of 1.0 mm to 4.0 mm.

12. The method of claim 8 wherein the primary scaffold is present at 10.0% to 20.0% by volume.

13. The method of claim 8 wherein said biomaterial has a porosity of 50% to 90% by volume.

14. The method of claim 8 wherein said biomaterial further comprises at least one of a protein and a carbohydrate.